Phase II Trial of Pembrolizumab in Recurrent or Metastatic HNSCC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A single-arm phase II trial to assess the efficacy and safety profile of pembrolizumab in
patients with performance status of 2 with recurrent or metastatic squamous cell carcinoma of
the head and neck. Patients will receive best supportive care + pembrolizumab 200mg every 3
weeks for a maximum duration of 24 months